$1.49
-0.06-3.87%
Last update: Nov 12, 7:25 PM
Can Fite Biopharma Ltd (CANF) Stock Price, Quote, News & History
CANFAMEX
Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
You can purchase shares of Can Fite Biopharma (AMEX:CANF) through any online brokerage.
Other companies in Can Fite Biopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Can Fite Biopharma has a consensus price target of $143.75.
The stock price for Can Fite Biopharma (AMEX: CANF) is $1.57 last updated November 12, 2026 at 7:25 PM EST.
There are no upcoming dividends for Can Fite Biopharma.
Can Fite Biopharma does not have any upcoming earnings scheduled.
There is no upcoming split for Can Fite Biopharma.
Can Fite Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and...
